PERSONALIS INC (PSNL) Stock News

USA - NASDAQ:PSNL - US71535D1063 - Common Stock

8.9429 USD

-0.7 (-7.23%)

Last: 11/3/2025, 11:19:35 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PSNL Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Personalis, Inc.

Personalis to Announce Third Quarter 2025 Financial Results

18 days ago - By: Personalis, Inc.

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

2 months ago - By: Personalis, Inc.

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: The Motley Fool

Personalis (PSNL) Q2 Revenue Falls 24%

3 months ago - By: Benzinga - Mentions: AFG CXDO YUM PACK ...

Earnings Scheduled For August 5, 2025

2 months ago - By: Personalis, Inc.

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

2 months ago - By: Personalis, Inc.

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

2 months ago - By: Personalis, Inc.

Personalis to Participate in Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research

Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)

6 months ago - By: Benzinga

Analyst Expectations For Personalis's Future

3 months ago - By: Zacks Investment Research

After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)

3 months ago - By: Zacks Investment Research

All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy

3 months ago - By: Personalis, Inc.

Personalis Reports Second Quarter 2025 Financial Results

3 months ago - By: Personalis, Inc.

Personalis to Announce Second Quarter 2025 Financial Results

4 months ago - By: Personalis, Inc.

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Yahoo Finance - Mentions: TEM BAC

Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer

4 months ago - By: Personalis, Inc.

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

5 months ago - By: Personalis, Inc.

Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

5 months ago - By: Personalis, Inc.

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

6 months ago - By: Personalis, Inc.

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

6 months ago - By: Personalis, Inc.

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

6 months ago - By: Zacks Investment Research - Mentions: TSHA

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

6 months ago - By: Personalis, Inc.

Personalis Reports First Quarter 2025 Financial Results